Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
21 mars 2024 06h00 HE
|
Bionomics Ltd
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over...
Bionomics to Present at the 2024 BIO CEO & Investor Conference
22 févr. 2024 16h30 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
Bionomics Provides a Review of 2023 and of 2024 Plans
22 janv. 2024 06h00 HE
|
Bionomics Ltd
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food &...
Bionomics to Present at Biotech Showcase™ 2024
05 janv. 2024 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
06 déc. 2023 08h00 HE
|
Bionomics Ltd
A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the...
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
16 oct. 2023 08h00 HE
|
Bionomics Ltd
Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms...
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
28 sept. 2023 06h00 HE
|
Bionomics Ltd
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints...
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
14 sept. 2023 06h00 HE
|
Bionomics Ltd
Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the learnings from Bionomics’ candidate BNC375,...
Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210
23 août 2023 06h00 HE
|
Bionomics Ltd
The last patient last visit has been completed in the Phase 2b ATTUNE study of BNC210 for the treatment of PTSDTopline results from Phase 2b ATTUNE study of BNC210 in patients with PTSD are expected...
Quarterly Activities and Cashflow Report
31 juil. 2023 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, and CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO), (Bionomics or the Company) a clinical-stage biopharmaceutical company...